- The magazine
Oral drug delivery for Macromolecules using softgel lipid delivery systems to be presented by Catalent expert
Publication date: 28 November 2012
Author: Catalent Pharma Solutions
Jeffrey E. Browne, Ph.D., R&D Director, US Platform Leader, Pharma Softgel at Catalent Pharma Solutions, will be presenting “Softgel Lipid-based Drug Delivery Systems: A Promising Technology for the Oral Delivery of Macromolecules,” at the Formulation and Drug Delivery Systems for Peptide and Protein Conference being held in San Diego on December 3-5, 2012.
Dr. Browne will discuss how to overcome the obstacles presented by the gastro-intestinal tract for the successful oral delivery of macromolecules. He will also explain the role permeation-enabled lipid-based formulations can play in achieving adequate oral absorption and how to ensure the optimal drug delivery strategy for macromolecules using softgel technologies.
Throughout his career, Dr. Browne has held various positions in pharmaceutical manufacturing and technical services, as well as drug delivery R&D, with a focus on topical, transdermal, inhalation and oral liquid dosage forms. In 1994, Dr. Browne joined Catalent Pharma Solutions and has expanded his expertise in a variety of positions including: VP Softgel R&D; Executive Director & Division Head of Pharmaceutical Development; Director of Technical Services; Account Director, Business Development; and Technical Director, Pharmaceutical Softgels. Dr. Browne holds a Ph.D. in Industrial & Physical Pharmacy from Purdue University.
For more information or to register for the conference, visit: www.marcusevans.com
If you enjoyed this article sign-up to receive our bi-weekly email newsletter:
- Daiichi Sankyo submits a New Drug Application in Japan for the antiplatelet agent prasugrel (18 June 2013)
- Sanofi to present new clinical data at the American Diabetes Association 73rd Scientific Sessions (18 June 2013)
- AstraZeneca selects location for new global R&D centre and corporate headquarters in Cambridge, UK (18 June 2013)
- Johnson & Johnson announces definitive agreement to acquire Aragon Pharmaceuticals, Inc. (17 June 2013)
- Gilead announces interim Phase 2 data for Idelalisib (17 June 2013)
ABB Analytical Measurements | Analytik Jena AG | Aptalis Pharmaceutical Technologies | ASM - Aerosl-Service AG | Azbil BioVigilant, Inc. | B&W Tek, Inc. | Bio-Optronics, Inc. | bioMérieux | BioTrends – Archilex SA | BMG LABTECH GmbH | Bruker Daltonik GmbH | CAMO Software AS | Catalent Pharma Solutions | Chemical Plant Equipment | Chemspec Europe Ltd | CI Precision | Dow Chemical Company Ltd | DSM Biologics | FOSS NIRSystems, Inc. | GE Analytical Instruments | GenScript USA Inc. | Gerresheimer Group | HACH LANGE GMBH | HAMAMATSU PHOTONICS EUROPE | I Holland Limited | IDBS | IONIMED Analytik GmbH | Lonza | MPI Research | Natoli Engineering Company, Inc. | Pall Life Sciences | PANalytical B.V. | Patheon Inc | ReAgent | Roche | Siemens AG | Sirius Analytical Instruments Ltd | TSI | Vala Sciences | Veltek Associates Inc. | Waters Corporation |